Polypeptides are compounds formed by multiple amino acids linked through peptide bonds, typically consisting of 10 to 100 amino acids with a molecular weight below 10,000. Polypeptides are widely present in living organisms and play important roles in regulating the functions of various systems, organs, tissues, and cells. With advances in biotechnology and polypeptide synthesis, more polypeptide-based drugs have been developed and applied clinically, becoming new treatment options for a variety of diseases.
I. Current Status of the Polypeptide Drug Industry
1.1 Market Size and Growth Trends
In recent years, the global polypeptide drug market has shown significant growth. According to the 2024-2029 China Polypeptide Drug Industry Deep Research and Investment Opportunity Analysis Report by Zhongyan Puhua Research Institute, the global polypeptide drug market grew from USD 56.8 billion in 2016 to USD 62.8 billion in 2020, with a compound annual growth rate (CAGR) of 2.6%. Since 2020, with the increasing adoption of novel polypeptide drugs such as semaglutide and teriparatide, the industry growth has accelerated significantly. The global market is expected to reach USD 96.0 billion by 2025, with a CAGR of 8.5%.
China’s polypeptide drug market is also expanding rapidly, growing from USD 6.3 billion in 2016 to USD 8.5 billion in 2020. It is projected to reach USD 26.7 billion by 2028, with a CAGR of 15.3%, significantly higher than the global average. This growth is driven by government support for polypeptide drug R&D, improved medical insurance systems, and increased patient demand for high-quality and effective drugs.
1.2 Applications of Polypeptide Drugs
Due to their unique pharmacological properties, polypeptide drugs are applied in multiple disease areas:
Cancer treatment: Polypeptide drugs such as antitumor peptides and peptide vaccines specifically target cancer cells, inhibit their growth and spread, and reduce the side effects of conventional chemotherapy.
Diabetes treatment: Polypeptide drugs represented by GLP-1 receptor agonists mimic naturally secreted GLP-1 hormones, promoting insulin secretion while inhibiting glucagon release, effectively lowering blood glucose levels.
Cardiovascular and cerebrovascular diseases: Polypeptide drugs, including antithrombotic and antihypertensive peptides, inhibit platelet aggregation and thrombus formation, reduce blood pressure and lipid levels, and prevent the development of cardiovascular diseases.
Hepatitis treatment: Polypeptide drugs such as antiviral and immunomodulatory peptides inhibit viral replication, enhance immunity, and improve patient prognosis.
1.3 Technological Innovation and Production Processes
Technological innovation is key to the development of polypeptide drugs. From biological extraction to chemical synthesis and genetic recombination, production technologies have continuously improved. In particular, solid-phase synthesis has become the mainstream production method, increasing efficiency and purity through automated and semi-automated processes.
Purification technologies have also advanced, with traditional methods like ion exchange and gel filtration gradually replaced by higher-efficiency techniques such as affinity chromatography and reversed-phase chromatography, improving purification efficiency and lowering production costs.
II. Competitive Landscape of the Polypeptide Drug Industry
2.1 Coexistence of Domestic and International Companies
Both domestic and international companies operate in the polypeptide drug market. Foreign companies such as Novartis, Amgen, and Lonza maintain advantages, while domestic companies like HanYu Pharma, Zhonghe Pharma, Shuangcheng Pharma, and SinoBio are rapidly emerging. Local companies leverage deep market knowledge, flexible marketing strategies, and growing R&D capabilities to gain market share.
2.2 Intense Market Competition
Domestic polypeptide drug companies are numerous but mostly small in scale, resulting in low market concentration and fierce competition. Companies increase R&D investments, optimize product portfolios, and enhance competitiveness. As patents for several major polypeptide drugs expire, generic drug opportunities will further intensify competition.
2.3 Changing Competitive Landscape
Recently, new polypeptide drugs, especially GLP-1 receptor agonists, have emerged as market leaders due to high efficacy and safety. As more GLP-1 pipelines are commercialized and new drug technologies like PRC and PDC mature, the competitive landscape is expected to evolve further.
III. Future Development Trends and Prospects
3.1 Technological Advancements Driving Growth
Advances in biotechnology and polypeptide synthesis will make R&D and production more efficient and convenient. More novel polypeptide drugs are expected to be developed and applied clinically, broadening therapeutic applications. Improvements in purification and formulation technologies will increase purity, stability, and reduce costs, providing high-quality options to patients.
3.2 Sustained Market Demand
Rising global prevalence of chronic diseases such as diabetes, obesity, and cancer will continue to boost market demand, especially for cancer, diabetes, and cardiovascular drugs. Increased health awareness and improved insurance systems further support demand for high-quality, effective polypeptide drugs.
3.3 Policy Support
Government policies increasingly support new drug development and medical innovation. China has included polypeptide drugs as a priority in initiatives like Made in China 2025 and the Industrial Structure Adjustment Guidance Catalog, offering incentives and regulatory guidance, such as the Technical Guidelines for Pharmaceutical Research of Chemically Synthesized Polypeptide Drugs (Trial).
3.4 Intensifying Global Competition
As the global polypeptide drug market expands, competition between domestic and foreign companies intensifies. Companies strengthen international cooperation and R&D, improve product quality, and optimize technology. Multinational pharmaceutical companies use mergers, acquisitions, and strategic partnerships to expand globally and consolidate resources.
3.5 Broad Future Prospects
The polypeptide drug industry is expected to maintain rapid growth and become an important segment of the pharmaceutical market. Technological advances and market expansion will lead to wider applications across disease areas, offering patients more treatment options. Intensified domestic and international competition, along with deeper collaboration, will enhance overall industry strength and contribute significantly to global pharmaceutical development.
For an in-depth industry analysis of polypeptide drugs, please refer to the Zhongyan Puhua Research Institute’s 2024-2029 China Polypeptide Drug Industry Deep Research and Investment Opportunity Analysis Report.
